Different cancer indications can be targeted by inobrodib as a monotherapy or in combination with existing standard of care drugs
Late stage prostate cancer - metastatic Castration Resistant Prostate Cancer (mCRPC)
Haematological cancers - Relapsed/refractory haematological cancers including Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) and Diffuse Large B-cell Lymphoma (DLBCL)
Tumours driven by specific genomic alterations – inobrodib can specifically target tumours with amplified Myc or Androgen Receptor (AR), bearing ARID1A mutations or tumours with p300/CBP loss of function mutations.
Identification of further relevant cancer types is ongoing – e.g. lung, breast, salivary duct